Skip to content

Structural and functional MRI in Parkinson*s disease and healthy carriers with GBA mutation, an exploratory study

Structural and functional MRI in Parkinson*s disease and healthy carriers with GBA mutation, an exploratory study - Cerebral correlates of GBA mutations.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON49472
Enrollment
80
Registered
2020-10-08
Start date
2022-10-25
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Sponsors

Radboud Universiteit Nijmegen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Subjects participating and consented in the Luxembourg Parkinson*s Study. -Subjects of both genders with a full capacity of consent for MRI data collection and analysis. -The participants fall within one of the four targeted groups (Parkinson patients and healthy controls with and without GBA gene mutation) -Use of anti-parkinsonian medication (for PD patients) • Age 18 years or older

Exclusion criteria

Exclusion criteria: -Subjects who are not consented participants in Luxembourg Parkinson*s Study. -Refusal to sign the informed consent for MRI data collection and analysis. -Contraindication for MRI data collection (metal implants, pacemakers, etc...)

Design outcomes

Primary

MeasureTime frame
Motor task-related brain activity as a function of genotype (with or without GBA mutations) and disease (with or without PD).

Secondary

MeasureTime frame
Reward task-related brain activity as a function of genotype (with or without GBA mutations) and disease (with or without PD). Motor and reward task-related cerebral activity as a function of medication status in PD patients (ON vs. OFF medication). Structural MRI measures as a function of genotype (with or without GBA mutations) and disease (with or without PD).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)